Alzheimer's, Alector

Alector turns to layoffs as Alzheimer’s drug fails
The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align resources” with its strategic priorities.
Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's disease. Its drug failed the Phase 2 trial.
Trial of controversial Alzheimer’s drug halted after disappointing results
Cassava Sciences announced Monday that the drug, simufilam, did not significantly reduce cognitive decline in people with mild to moderate Alzheimer’s disease in the trial.
Alector Plummets After Alzheimer's Drug Trial Fails Primary Endpoint
Alector said that, in addition to failure to meet the primary endpoint of the study, no treatment effects favored AL002 on secondary clinical and functional endpoints. The company said it had $457.2 million worth of cash,
Cassava to stop trials of Alzheimer's drug after late-stage study failure
(Reuters) -Cassava Sciences said on Monday it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer plummeting more than 80% before the bell.
Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study
KEY TAKEAWAYS Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its experimental Simufilam drug aimed at treating Alzheimer’s disease failed a late-stage study.
FierceBiotech19h
UPDATED: Alector lays off 17% of staff after AbbVie-partnered Alzheimer's asset fails phase 2
Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...
BioSpace16h
Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II, Triggering a 17% Layoff
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
Yahoo Finance14h
Alector stock drops after Alzheimer’s drug fails in Phase II trial
Alector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, ...
Alector’s Strategic Pipeline and Promising PGRN Program Justify Buy Rating Despite AL002 Setback
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...
STAT1d
Roche’s TIGIT troubles continue, a novel Alzheimer’s target misses the mark, and other biotech news
Alector Therapeutics said that its Phase 2 trial for an experimental Alzheimer’s antibody failed, dealing a blow to what ...
Business Insider19h
Buy Rating Maintained for Alector Despite AL002 Setback, Focus on Promising AL001 and Strong Financials
Don't Miss our Black Friday Offers: Graig Suvannavejh’s rating is based on several strategic considerations despite the recent disappointing data for Alector’s AL002. Although the Phase 2 results ...
Fintel on MSN7h
Morgan Stanley Downgrades Alector (ALEC)
Fintel reports that on November 26, 2024, Morgan Stanley downgraded their outlook for Alector (NasdaqGS:ALEC) from ...
bovnews16h
Alector Inc (ALEC) Posted -257.54% Profit Margin Last Year—Can It Hold Up?
On Monday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $3.96 which represents a slight increase of $0.02 or 0.51% from the prior close of $3.94. The stock opened at $4.01 and ...
pharmaphorum4y
Alector launches $208m fundraiser for Alzheimer's R&D with AbbVie
Alector has launched an $208 million stock market offering as it ramps up clinical trials with AbbVie into a drug that aims to tackle Alzheimer’s by modifying the brain’s immune system.
Business Insider23h
Alector’s Strategic Innovations and Potential in Neurological Treatments Justify Buy Rating
BTIG analyst Thomas Shrader maintained a Buy rating on Alector (ALEC – Research Report) yesterday and set a price target of $5.00. Don't Miss our Black Friday Offers: Unlock your investing potential ...